Fly News Breaks for February 5, 2020
Feb 5, 2020 | 17:03 EDT
Mizuho analyst Vamil Divan initiated coverage of Neurocrine with a Neutral rating and $107 price target. The analyst notes that while Ingrezza has been a "clear success story" for the company, his proprietary survey of physicians suggests "less upside" relative to where consensus estimates are for the drug. Divan adds that another survey for Orilissa suggests that sales should accelerate after a slow start, but notes that Neurocrine gets "only a portion of economics" from the product. The analyst further states that more positive pipeline surprises could turn him more constructive on the shares.
News For NBIX From the Last 2 Days
There are no results for your query NBIX